Merck & Co., Inc. $MRK Stock Purchased by Park Avenue Securities LLC

Park Avenue Securities LLC boosted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 6.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,282 shares of the company’s stock after buying an additional 7,416 shares during the period. Park Avenue Securities LLC’s holdings in Merck & Co., Inc. were worth $16,606,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of MRK. Round Rock Advisors LLC boosted its position in shares of Merck & Co., Inc. by 0.7% during the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after acquiring an additional 66 shares in the last quarter. Cypress Wealth Services LLC raised its position in Merck & Co., Inc. by 0.5% in the third quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock worth $1,960,000 after purchasing an additional 69 shares in the last quarter. Code Waechter LLC lifted its stake in Merck & Co., Inc. by 3.4% during the third quarter. Code Waechter LLC now owns 2,179 shares of the company’s stock worth $317,000 after purchasing an additional 71 shares during the period. Cascade Financial Partners LLC lifted its stake in Merck & Co., Inc. by 0.5% during the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after purchasing an additional 80 shares during the period. Finally, Somerset Trust Co lifted its stake in Merck & Co., Inc. by 0.9% during the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after purchasing an additional 81 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Buying and Selling

In other news, EVP Chirfi Guindo sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the transaction, the executive vice president directly owned 46,613 shares of the company’s stock, valued at $6,106,303. The trade was a 24.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the sale, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 228,238 shares of company stock valued at $29,977,783 in the last ninety days. 0.17% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on MRK shares. Berenberg Bank upped their price objective on Merck & Co., Inc. from $127.00 to $137.00 and gave the company a “hold” rating in a research note on Friday, September 11th. Citigroup raised their target price on Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a research report on Monday, October 12th. Guggenheim raised their target price on Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. The Goldman Sachs Group boosted their price target on Merck & Co., Inc. from $140.00 to $160.00 and gave the company a “buy” rating in a research note on Friday, August 21st. Finally, Sanford C. Bernstein upped their price target on Merck & Co., Inc. from $100.00 to $105.00 and gave the company a “market perform” rating in a research report on Tuesday, August 4th. Seventeen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $153.12.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $141.83 on Wednesday. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92. The firm has a 50-day moving average price of $146.90 and a 200 day moving average price of $126.16.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc.’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts predict that Merck & Co., Inc. will post 2.64 EPS for the current year.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna’s personalized melanoma vaccine reduced the risk of recurrence or death by 42% when added to Keytruda in a Phase 3 trial. The result supports Merck’s strategy of using new therapies to help extend Keytruda’s commercial franchise, although the benefit was below some investor expectations. Merck and Moderna’s Cancer Vaccine Worked—Who Gets Paid?
• Positive Sentiment: Merck reported promising Phase 3 results for sacituzumab tirumotecan, which reduced the risk of death by 32% and disease progression or death by 41% versus chemotherapy in certain advanced or recurrent endometrial cancer patients. The data could expand Merck’s oncology pipeline, with an FDA decision expected by June 2027. Sacituzumab Tirumotecan Phase 3 Results
• Positive Sentiment: Barclays raised its MRK price target from $150 to $180 and maintained an “overweight” rating, citing potential from Merck’s oncology pipeline and vaccine partnership. Barclays Stock Recommendations
• Neutral Sentiment: Investors are focused on Merck’s Q3 results, particularly Keytruda sales, Winrevair growth, full-year guidance and management’s plans to commercialize the melanoma vaccine. Keytruda remains a major growth engine, but the company’s shares sit below their 50-day moving average ahead of the report. Is Merck Stock a Buy, Sell or Hold Ahead of Q3 Earnings?
• Negative Sentiment: Despite strong Keytruda and newer-drug sales, analysts are lowering estimates amid Gardasil weakness and concerns about Keytruda’s patent expiry in December 2028. The personalized vaccine may help retain patients, but its potential revenue would be modest relative to Keytruda’s franchise.
• Negative Sentiment: The melanoma vaccine’s 42% recurrence-risk reduction was below the roughly 49% result from its earlier trial, tempering enthusiasm. Merck’s shares were relatively resilient compared with Moderna because the program’s potential earnings contribution is less material to Merck.
• Negative Sentiment: New U.S. restrictions on certain China biotechnology collaborations could limit Merck’s access to potential drug candidates and research partnerships, adding longer-term pipeline and sourcing uncertainty. What Do New China Biotech Curbs Mean For Merck Stock?

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.